Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)

MK0928 Phase II Sleep Laboratory Study - Primary Insomnia

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00266357

Enrollment

Registered

2005-12-16

Start date

2005-11-30

Completion date

Unknown

Last updated

2015-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Insomnia

Brief summary

A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.

Interventions

DRUGMK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)

DRUGPlacebo / Duration of Treatment: 2 days for screening period

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

20 Years to 64 Years

Healthy volunteers

Inclusion criteria

* Patients with a diagnosis of primary insomnia

Exclusion criteria

* Patients with an active psychiatric disorder other than primary insomnia

Design outcomes

Primary

Measure	Time frame
Mean of total sleep time over 2 nights.	—

Secondary

Measure	Time frame
Mean of other PSG sleep parameters over 2 nights, mean of subjective sleep parameters, and exploratory residual effect.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026